Middle East and Africa Fibrotic Disease Treatment Market - Industry Trends and Forecast to 2032

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Middle East and Africa Fibrotic Disease Treatment Market - Industry Trends and Forecast to 2032

  • Pharmaceutical
  • Published Report
  • Dec 2024
  • MEA
  • 350 Páginas
  • Número de tablas: 78
  • Número de figuras: 29

Middle East And Africa Fibrotic Diseases Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2025 –2032
Diagram Tamaño del mercado (año base)
USD 106.04 Million
Diagram Tamaño del mercado (año de pronóstico)
USD 155.99 Million
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Middle East and Africa Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others) - Industry Trends and Forecast to 2032

Middle East and Africa Fibrotic Diseases Treatment Market

Middle East and Africa Fibrotic Disease Treatment Market Analysis

The rising prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis, is a significant driver of the fibrotic diseases treatment Market. Factors such as aging populations, lifestyle changes, and increasing rates of chronic conditions like diabetes and hypertension are contributing to a higher incidence of these diseases. As the number of affected individuals grows, the demand for effective treatments intensifies, driving the need for advanced therapies, including antifibrotic drugs and biologics. Healthcare systems face growing pressure to manage chronic fibrotic conditions, driving demand for more effective treatments and fueling market growth.

Middle East and Africa Fibrotic Disease Treatment Market Size

The Middle East and Africa fibrotic disease treatment market is expected to reach USD 155.99 million by 2032 from USD 106.04 million in 2024, growing at a CAGR of 5.1% in the forecast period of 2025 to 2032.

Middle East and Africa Fibrotic Disease Treatment Market Trends

“Rising Adoption of Biomarker-Based Diagnostics”

The use of biomarker-based diagnostics in Testicular Germ Cell Tumors (TGCT) is becoming more prevalent, with biomarkers such as alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH) playing a crucial role in clinical practice. These biomarkers enable clinicians to achieve early detection, monitor disease progression, and tailor treatments to the individual characteristics of each patient. This trend reflects advancements in precision medicine and is leading to more accurate staging and risk stratification of TGCT. As research continues to identify additional biomarkers, the integration of these diagnostic tools is becoming a standard approach, enhancing treatment protocols and improving patient outcomes.

Middle East and Africa Fibrotic Disease Treatment Market Segmentation           

Attributes

Middle East and Africa Fibrotic Disease Treatment Market Insights

Segments Covered

  • By Treatment: Medication, Organ Transplantation, Oxygen Therapy, and Others
  • By Application: Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others
  • By End User: Hospitals, Specialty Clinics, Academic and Research Institutes, and Others

Countries Covered

South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and Rest of Middle East and Africa

Key Market Players

C.H. Boehringer Sohn AG & Co. KG. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Accord Healthcare (U.K.), AbbVie Inc. (U.S.), Redx Pharma Pic (U.K.), Bristol-Myers Squibb Company (U.S.), BioMX (U.S.), KITHER BIOTECH S.R.L. (Italy), Verona Pharma pic (U.K.), Intercept Pharmaceuticals, Inc. (U.S.)

Market Opportunities

  • Rising research and development activities
  • Advancements in pipeline drug developments
  • Increasing strategic collaborations and partnerships

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Fibrotic Disease Treatment Market Definition

Fibrotic disease is a condition where excessive fibrous connective tissue (fibrosis) forms, often as a result of chronic inflammation or tissue injury. This abnormal tissue build-up disrupts the normal function of organs, commonly affecting the lungs (pulmonary fibrosis), liver (liver fibrosis), heart, kidneys, and skin.

Treatment for fibrotic disease focuses on slowing or halting the progression of fibrosis, reducing inflammation, and managing symptoms. Approaches may include anti-fibrotic drugs, immunosuppressive agents, lifestyle modifications, and in advanced cases, surgical options like organ transplantation. Newer treatments explore targeted therapies that block specific pathways responsible for fibrosis development.

Middle East and Africa Fibrotic Disease Treatment Market Dynamics

Drivers  

  • Rising Prevalence of Fibrotic Diseases

The rising prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis, is a significant driver of the Fibrotic Diseases Treatment Market. Factors such as aging populations, lifestyle changes, and increasing rates of chronic conditions like diabetes and hypertension are contributing to a higher incidence of these diseases. As the number of affected individuals grows, the demand for effective treatments intensifies, driving the need for advanced therapies, including antifibrotic drugs and biologics. Healthcare systems face growing pressure to manage chronic fibrotic conditions, driving demand for more effective treatments and fueling market growth.

For instance,

  • In January 2023, according to an article published by PubMed Central, the incidence and prevalence of idiopathic pulmonary fibrosis (IPF) are rising globally, no longer fitting its rare disease classification. In North America, prevalence rates range from 2.4 to 2.98 per 10,000 people, with South Korea having the highest prevalence at 4.51 per 10,000

The rising prevalence of fibrotic diseases significantly fuels market expansion by highlighting the need for better, more accessible treatment solutions, while also encouraging increased research and development in the field.         

  • Increase in the Number of People Smoking Cigarettes

Cigarette smoking is one of the most recognized risk factors for development of idiopathic pulmonary fibrosis (IPF). Furthermore, recent work suggests that smoking may have a detrimental effect on survival of patients with IPF. The mechanism by which smoking may contribute to the pathogenesis of IPF is largely unknown. However, accumulating evidence suggests that increased oxidative stress might promote disease progression in IPF patients who are current and former smokers.

For instance,

  • In June 2023, according to an article published by NCBI, smoking is a key risk factor for interstitial lung diseases (ILDs) like idiopathic pulmonary fibrosis (IPF), with studies indicating that 41% to 83% of IPF patients have a smoking history and a 60% higher risk
  • In May 2022, according to the article published in National Center for Biotechnology Information (NCBI), Smoking has been considered an important risk factor for idiopathic pulmonary fibrosis (IPF) incidence. According to the study conducted in the article the risk of IPF was significantly higher in current and former smokers than in never smokers, with an aHR of 1.66 (95% CI 1.61 to 1.72) and 1.42 (95% CI 1.37 to 1.48), respectively. Current smokers had a higher risk of IPF than former smokers (aHR 1.17, 95% CI 1.13 to 1.21). The risk of IPF development increased as the smoking intensity and duration increased

Opportunities

  • Rising Research and Development Activities

The increasing prevalence of fibrotic diseases and the demand for more effective treatments are prompting pharmaceutical and biotech companies to boost their R&D investments. These efforts aim to develop innovative therapies, including new antifibrotic drugs, biologics, and gene therapies targeting the underlying causes of fibrosis. Additionally, advancements in personalized medicine and diagnostic technologies are expected to improve treatment outcomes and overall patient care. As R&D progresses, new therapeutic options will emerge, boosting market growth and improving the management of fibrotic diseases.

For instance,

  • In May 2024, according to Boehringer Ingelheim International GmbH, Boehringer Ingelheim has secured a license agreement to develop a first-in-class treatment for fibro-inflammatory diseases, reinforcing its commitment to breakthrough therapies aimed at improving patient outcomes
  • In July 2021, according to the article published by Moez Ghumman et.al, existing oral therapies, pirfenidone and nintedanib, may attempt to improve the patients’ quality of life by mitigating symptoms and slowing disease progression, however chronic doses and systemic deliveries of these drugs can lead to severe side effects. The lack of effective treatment options calls for further investigation of restorative as well as additional palliative therapies for IPF. Nanoparticle-based sustained drug delivery strategies can be utilized to ensure targeted delivery for site-specific treatment as well as long-acting therapy, improving overall patient compliance

The rise in R&D activities presents a major opportunity to accelerate market expansion by fostering innovation and enhancing treatment strategies.

  • Advancements in Pipeline Drug Developments

A growing number of promising therapies, including new antifibrotic drugs, biologics, and gene therapies, are currently in various stages of development. These drugs aim to target the underlying causes of fibrotic diseases, offering the potential for more effective treatments and improved patient outcomes, particularly for conditions like idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis. The successful approval and commercialization of these drugs will expand the range of therapeutic options available, meet the increasing demand for better treatments, and foster market growth.

For instance,

  • In September 2024, according to an article published by the Pulmonary Fibrosis Foundation, drugs like AP01, BBT-877, GKT137831, and others are currently in Phase 2 of development for fibrotic diseases
  • In February 2022, according to NCBI, a Phase I/II clinical trial, started in February 2021, is testing Imatinib (200mg/day) for advanced liver fibrosis (grades 3-4) at Taleghani Hospital in Tehran. The trial compares Imatinib with standard treatment and a placebo over 24 weeks

This study underscores the advancement in pipeline drug development, potentially introducing a novel treatment for liver fibrosis, which could fuel growth in the global fibrotic diseases treatment market

The advancements in pipeline drug developments are poised to significantly drive market expansion by offering innovative solutions for the management of fibrotic diseases.

Restraints/Challenges

  • High Cost of Medication and Treatments

Fibrotic disease treatments have become increasingly expensive due to the growing number of patients suffering from fibrosis and the risen prices of medical devices and medications. The modern technological devices used in fibrosis treatment is also playing significant role in high prices of treatments, and high accuracy, provide a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). Therefore, the high cost of medications and treatment procedure for fibrotic disease is hampering the growth of the market.

For instance,

  • In October 2022, according to an article published by PubMed Central, therapeutic options for IPF are limited, with only two approved antifibrotic drugs—pirfenidone and nintedanib—available for mild to moderate cases. These drugs are costly, ranging from USD2,000 to USD14,000 per person monthly, depending on the country
  • In September 2022, according to the article published by Alan Katz et.al, cost per treatment of the hyperbaric oxygen therapy will generally range between USD 250-USD 600 per treatment depending on a few factors, including the number of sessions and location of services
  • In January 2022, according to an article published in BMC Pulmonary Medicine reported that the annual list price of pirfenidone was approximately USD 36,070.80, whereas the annual cost for both pirfenidone and nintedanib in the U.S. exceeds USD 100,000, and in Belgium, the annual list price of nintedanib is around USD 28,910. This high cost of medications and treatments is expected to act as a restraint for the global fibrotic diseases treatment market, limiting access to these therapies and placing financial strain on patients and healthcare systems

The Complex and Multifactorial Nature of Fibrotic Diseases

Fibrosis is driven by a variety of factors, including genetic predispositions, environmental exposures, and underlying chronic conditions, making it difficult to pinpoint a single cause or develop a one-size-fits-all treatment. This complexity complicates the development of effective therapies that can address the diverse mechanisms involved in fibrosis. Additionally, the progressive and often asymptomatic nature of these diseases until advanced stages further complicates early diagnosis and treatment, leading to delayed interventions.

For instance,

  • In January 2023, according to an article published by PubMed Central, in IPF, normal lung tissue is replaced by abnormal matrix build up, impairing alveolar function and leading to respiratory failure. Repeated micro-injuries and disrupted cell repair drive irreversible lung damage

The multifaceted nature of fibrotic diseases requires a highly tailored approach to treatment, posing a challenge for pharmaceutical companies to develop universally effective therapies and strategies to manage these conditions.

Middle East and Africa Fibrotic Disease Treatment Market Scope

The market is segmented on the basis of treatment, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. 

This research report categorizes the Middle East and Africa Fibrotic Disease Treatment market into the following segments:

By Treatment

  • Medication
    • Nintedanib (OFEV)
    • Pirfenidone (ESBRIET)
  • Organ Transplantation
  • Oxygen Therapy
  • Others

By Application

  • Idiopathic Pulmonary Fibrosis
  • Hepatic Cirrhosis
  • Renal Fibrosis
  • Cutaneous Fibrosis
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Academic and Research Institutes
  • Others

Middle East and Africa Fibrotic Disease Treatment Market Regional Analysis

The market is segmented on the basis of treatment, application, and end user.

The countries covered in the market are South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and rest of Middle East and Africa.

South Africa is expected to dominate and fastest growing country due to its well-established healthcare infrastructure, high prevalence of fibrotic diseases such as idiopathic pulmonary fibrosis and liver fibrosis, and robust investment in research and development.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Middle East and Africa Fibrotic Disease Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Middle East and Africa Fibrotic Disease Treatment Market Leaders Operating in the Market Are:

  • C.H. Boehringer Sohn AG & Co. KG. (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sandoz International GmbH (Germany)
  • Accord Healthcare (U.K.)

Latest Developments in Middle East and Africa Fibrotic Disease Treatment Market

  • In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other global authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio
  • In July 2024, Teva and Sanofi announced an updated timeline for the anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program strengthens both companies’ positions in the IBD treatment market, potentially expanding their offerings in immunology
  • In November 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. This has helped the company to expand globally
  • In March 2022, Genentech, a member of the Roche Group announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. This has helped the company to expand globally


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS

5.1 NORTH AMERICA

5.1.1 U.S.

5.1.2 CANADA

5.2 EUROPE

5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)

5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)

5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)

5.3 ASIA-PACIFIC

5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)

5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)

5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)

5.4 LATIN AMERICA

5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)

5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)

5.5 MIDDLE EAST AND AFRICA (MEA)

5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES

6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES

6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES

6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES

6.2 RESTRAINTS

6.2.1 HIGH COST OF MEDICATION AND TREATMENTS

6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES

6.3 OPPORTUNITIES

6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES

6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS

6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS

6.4 CHALLENGES

6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.

6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,

7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 MEDICATION, BY TREATMENT

7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL

7.3 ORGAN TRANSPLANT

7.4 OXYGEN THERAPY

7.5 OTHERS

8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 IDIOPATHIC PULMONARY FIBROSIS

8.3 HEPATIC CIRRHOSIS

8.4 RENAL FIBROSIS

8.5 CUTANEOUS FIBROSIS

8.6 OTHERS

9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALTY CLINICS

9.4 ACADEMIC AND RESEARCH INSTITUTES

9.5 OTHERS

10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY REGION

10.1 MIDDLE EAST AND AFRICA

11 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 SWOT ANALYSIS

13 COMPANY PROFILE

13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

13.2.1 COMPANY SNAPSHOT

13.2.2 COMPANY SHARE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENTS

13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 COMPANY SHARE ANALYSIS

13.3.4 PRODUCT PORTFOLIO

13.3.5 RECENT DEVELOPMENTS

13.4 SANDOZ INTERNATIONAL GMBH

13.4.1 COMPANY SNAPSHOT

13.4.2 COMPANY SHARE ANALYSIS

13.4.3 PRODUCT PORTFOLIO

13.4.4 RECENT DEVELOPMENTS

13.5 ACCORD HEALTHCARE

13.5.1 COMPANY SNAPSHOT

13.5.2 COMPANY SHARE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENTS

13.6 ABBVIE INC.

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENTS

13.7 BRISTOL-MYERS SQUIBB COMPANY.

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENTS

13.8 BIOMX.

13.8.1 COMPANY SNAPSHOT

13.8.2 PRODUCT PORTFOLIO

13.8.3 RECENT DEVELOPMENTS

13.9 INTERCEPT PHARMACEUTICALS, INC.

13.9.1 COMPANY SNAPSHOT

13.9.2 REVENUE ANALYSIS

13.9.3 PRODUCT PORTFOLIO

13.9.4 RECENT DEVELOPMENTS

13.1 KITHER BIOTECH S.R.L.

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENTS

13.11 REDX PHARMA PLC.

13.11.1 COMPANY SNAPSHOT

13.11.2 REVENUE ANALYSIS

13.11.3 PRODUCT PORTFOLIO

13.11.4 RECENT DEVELOPMENTS

13.12 VERONA PHARMA PLC

13.12.1 COMPANY SNAPSHOT

13.12.2 REVENUE ANALYSIS

13.12.3 PRODUCT PORTFOLIO

13.12.4 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

Lista de Tablas

TABLE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 2 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 3 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)

TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)

TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 7 MIDDLE EAST AND AFRICA ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 9 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 12 MIDDLE EAST AND AFRICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 23 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 24 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 29 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 30 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 31 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 32 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 33 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 34 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 35 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 36 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 37 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 38 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 39 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 40 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 41 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 42 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 43 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 44 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 45 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 46 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 47 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 48 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 49 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 50 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 51 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 52 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 53 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 54 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 55 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 56 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 58 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 59 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 60 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 61 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 62 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 64 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 65 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 66 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 67 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 68 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 69 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 70 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 72 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 73 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)

TABLE 74 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)

TABLE 75 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 76 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 77 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 78 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

Lista de figuras

FIGURE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032

FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032

FIGURE 15 MARKET OVERVIEW

FIGURE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024

FIGURE 17 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)

FIGURE 18 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)

FIGURE 19 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024

FIGURE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)

FIGURE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)

FIGURE 23 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024

FIGURE 25 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 29 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

Middle East and Africa Fibrotic Disease Treatment Market size was valued at USD 0.10 Billion in 2024.
The Middle East and Africa Fibrotic Disease Treatment Market is projected to grow at a CAGR of 5.1% from 2025 to 2032.
Rising prevalence of fibrotic diseases and increase in the number of people smoking cigarettes are the major drivers for the market..
C.H. Boehringer Sohn AG & Co. KG., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Accord Healthcare, AbbVie Inc., Redx Pharma Pic, Bristol-Myers Squibb Company, BioMX, KITHER BIOTECH S.R.L., Verona Pharma pic, Intercept Pharmaceuticals, Inc., are the major companies among others operating in this market.
The countries covered in the market are South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, Bahrain, and rest of Middle East and Africa.